St. Louis, MO—June 9, 2017— Acera Surgical Inc., a pioneer in regenerative medicine that utilizes its proprietary nanotechnology platform to create products for the major tissue defect markets, today announced that Dwayne Montgomery has joined Acera’s Board of Directors. Mr. Montgomery is a seasoned executive who has significant experience with numerous public and private healthcare companies.
Mr. Montgomery brings a tremendous amount of global experience as a chief executive in high growth segments of healthcare to his role on the Acera Board. His accomplished career spans 25+ years in medical device and biotech executive management and is backed with a proven commercialization track record through business development, M&A, and capital raises with both domestic and international organizations.
“Dwayne is joining the team at a critical period for the company” says Agnes Rey-Giraud, co-founder and CEO of Acera, “Dwayne’s leadership and experience will be invaluable in helping us bring Acera’s innovative products to market, including our most recent FDA cleared product, the RestrataTM Wound Matrix. I look forward to pairing Dwayne’s talents with our experienced management team to advance our platform portfolio.”
Mr. Montgomery has led companies through significant growth periods with varying size, including large, mid-cap, and start-up ventures. Most recently, Mr. Montgomery served as the President and Chief Executive Officer for Osiris Therapeutics, Inc., a market leading company focused on advancing regenerative medicine. He was also a member of Osiris Therapeutics’ Board of Directors. Most notably, Mr. Montgomery orchestrated Osiris Therapeutics’ strategic partnerships with both Arthrex and Stryker, leaders in their respective healthcare segments. Mr. Montgomery graduated with a Bachelor of Science degree in chemistry from the University of North Alabama and attained a Master of Business Administration degree from Belmont University.
“I am excited to join the Acera Board at such a pivotal time for the company. Acera’s intellectual property portfolio and product development pipeline coupled with a successful commercial launch of the Restrata™ Wound Matrix positions Acera uniquely in the field of regenerative medicine,” remarked Dwayne.
About Acera Surgical Inc.
Acera Surgical Inc. (“Acera,” St. Louis, Missouri) is a bioscience company developing and commercializing a portfolio of fully synthetic electrospun scaffolds for regenerative medical applications. Acera’s products exhibit a structure similar to native extracellular matrix (ECM) and thus support rapid and effective healing. The FDA cleared Acera’s first product in March 2016 and its second product in April 2017, both via 510(k), granting commercial access to markets exceeding $1.2B in revenue. Acera is currently raising Series A financing and seeking commercialization partners.